Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

December 12, 2018 HEALTH CARE NOTEBOOK

Gaylord CEO named 'Healthcare Hero'

Photo | Sean Teehan Gaylord CEO George Kyriacou, 2018 Hartford Business Journal Healthcare Hero.
By Liese Klein

George Kyriacou, CEO of Gaylord Specialty Healthcare in Wallingford, has been named a Healthcare Hero by the Hartford Business Journal for his dedication to improving patient care.

Kyriacou was honored for improving the 137-bed hospital's financial outlook after arriving in late 2011, making it profitable within his first year, as well as for his focus on measurable patient results.

"I think what I contributed to the organization was really bringing it to a current state-of-the-art approach to delivering care, measuring care and achieving results clinically and operationally," Kyriacou said, crediting staff for helping forge Gaylord's success.

Under his watch, Gaylord expanded the use of technology in rehabilitation and expanded the its footprint in the region. Last month the hospital opened new housing for patient families after a successful fundraising campaign.

Kyriacou, who is slated to retire on Dec. 31, is credited both for his work at Gaylord and his impact on the rehabilitation sector.

"I don't think I've ever worked with anyone who has been as intensely concerned with positioning the hospital for the future, long term," said Gaylord Board of Directors member Peter Deckers, MD.

For more about George Kyriacou’s Healthcare Heroes award, read this Hartford Business Journal article.

Connecticut Hospital Association CEO named to diversity body

Jennifer Jackson, CEO of the Connecticut Hospital Association, has been appointed to the Board of Directors of the Institute for Diversity and Health Equity by the American Hospital Association.

Jackson will begin her term in January at the institute, which works with health-services organizations to advance health equity and to expand leadership opportunities for ethnic minorities in health management.

Jackson has served as CEO of CHA since 2000.

Yale Child Study Center partners with publisher on literacy research

A new initiative at the the Yale Child Study Center will focus on the intersection of literacy and health with the goal of improving academic and mental-health outcomes for children and their families.

The center has launched a joint research effort with Scholastic, a publisher of content for teachers and children, to be known as the Yale Child Study Center–Scholastic Collaborative for Child & Family Resilience.

“Health and literacy are deeply connected because a quality education is at the core of sustaining a healthy life,” said Yale Child Study Center Director Linda C. Mayes, MD. “This collaborative with Scholastic allows us to reach more families and communities with the information and resources they need to engage in literacy and enjoy healthy lives for themselves and for future generations.”

The research findings that come out of the collaborative will contribute to the creation of resources, programs, professional development and curriculum for supporting children and families.

Cutting-edge spectrometer debuts at Yale School of Public Health

Researchers at the Yale School of Public health expect breakthroughs from a new instrument, a cutting-edge mass spectrometer capable of identifying specific molecules within tissues. The new device — the only one at Yale — will be used to identify the connection between toxins in the environment and the onset of human disease.

The spectrometer was installed in the lab of Vasilis Vasiliou, chair of the department of Environmental Health Sciences and the Susan Dwight Bliss Professor of Epidemiology.

“This machine is the future of environmental health research,” Vasiliou said. “It allows us to see things that we never saw before.”

The device’s full name is the Waters SYNAPT G2-Si HDMS QToF with MALDI and DESI sources for tissue imaging mass spectrometry. Using laser irradiation, the instrument allows molecules in fresh-frozen or formalin-fixed tissue sections to be identified and localized in the tissue without the need to utilize molecule-specific reagents like antibodies, according to Vasiliou.

Vasilou’s lab will use the instrument in research on the molecular mechanisms underlying alcoholic liver disease, non-alcoholic steatohepatitis and hepatocellular carcinoma, in addition to work on the distribution of drugs delivered by novel nanoparticle formulations to treat glioblastoma.

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF